Kezar Life Sciences (KZR) Competitors $3.75 -0.05 (-1.32%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$3.75 0.00 (0.00%) As of 09/25/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KZR vs. BMEA, PYXS, EQ, FATE, ATOS, ZNTL, SPRO, ADAG, ANRO, and HLVXShould you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include Biomea Fusion (BMEA), Pyxis Oncology (PYXS), Equillium (EQ), Fate Therapeutics (FATE), Atossa Genetics (ATOS), Zentalis Pharmaceuticals (ZNTL), Spero Therapeutics (SPRO), Adagene (ADAG), Alto Neuroscience (ANRO), and HilleVax (HLVX). These companies are all part of the "pharmaceutical products" industry. Kezar Life Sciences vs. Its Competitors Biomea Fusion Pyxis Oncology Equillium Fate Therapeutics Atossa Genetics Zentalis Pharmaceuticals Spero Therapeutics Adagene Alto Neuroscience HilleVax Kezar Life Sciences (NASDAQ:KZR) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment. Does the media prefer KZR or BMEA? In the previous week, Biomea Fusion had 1 more articles in the media than Kezar Life Sciences. MarketBeat recorded 2 mentions for Biomea Fusion and 1 mentions for Kezar Life Sciences. Kezar Life Sciences' average media sentiment score of 1.89 beat Biomea Fusion's score of 1.08 indicating that Kezar Life Sciences is being referred to more favorably in the media. Company Overall Sentiment Kezar Life Sciences Very Positive Biomea Fusion Positive Which has preferable earnings & valuation, KZR or BMEA? Kezar Life Sciences has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKezar Life Sciences$7M3.92-$83.74M-$9.69-0.39Biomea FusionN/AN/A-$138.43M-$3.03-0.68 Which has more risk & volatility, KZR or BMEA? Kezar Life Sciences has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500. Do analysts rate KZR or BMEA? Kezar Life Sciences currently has a consensus target price of $9.00, indicating a potential upside of 140.00%. Biomea Fusion has a consensus target price of $14.44, indicating a potential upside of 604.61%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts clearly believe Biomea Fusion is more favorable than Kezar Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kezar Life Sciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Biomea Fusion 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.10 Is KZR or BMEA more profitable? Kezar Life Sciences' return on equity of -63.51% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets Kezar Life SciencesN/A -63.51% -52.13% Biomea Fusion N/A -243.95%-140.74% Do insiders and institutionals believe in KZR or BMEA? 67.9% of Kezar Life Sciences shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 10.4% of Kezar Life Sciences shares are owned by company insiders. Comparatively, 18.4% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryBiomea Fusion beats Kezar Life Sciences on 8 of the 15 factors compared between the two stocks. Get Kezar Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KZR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZR vs. The Competition Export to ExcelMetricKezar Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.83M$3.13B$5.74B$10.39BDividend YieldN/A2.39%5.75%4.64%P/E Ratio-0.3920.6375.7926.11Price / Sales3.92442.69550.48124.93Price / CashN/A44.6737.5461.24Price / Book0.239.6212.246.30Net Income-$83.74M-$52.73M$3.29B$271.03M7 Day Performance-0.27%1.81%0.28%-0.20%1 Month Performance-5.30%5.50%2.78%5.77%1 Year Performance-29.04%18.12%59.01%27.62% Kezar Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZRKezar Life Sciences3.8194 of 5 stars$3.75-1.3%$9.00+140.0%-31.7%$27.83M$7M-0.3960Positive NewsBMEABiomea Fusion3.3095 of 5 stars$1.96+1.6%$14.80+655.1%-76.6%$114.85MN/A-0.6550Positive NewsGap DownPYXSPyxis Oncology2.3761 of 5 stars$1.90+4.4%$7.75+307.9%-41.3%$112.87M$16.15M-1.1960Positive NewsEQEquillium0.6052 of 5 stars$1.71-8.6%$1.00-41.5%+72.8%$111.27M$16.55M-3.0540Positive NewsFATEFate Therapeutics3.8089 of 5 stars$0.96-0.8%$3.30+245.3%-71.9%$111.07M$13.63M-0.66550ATOSAtossa Genetics2.5222 of 5 stars$0.82-2.6%$6.17+653.7%-41.2%$108.48MN/A-3.568Positive NewsZNTLZentalis Pharmaceuticals1.7313 of 5 stars$1.45-2.7%$5.84+302.8%-60.4%$107.48M$67.43M-0.64160Positive NewsSPROSpero Therapeutics4.3372 of 5 stars$1.88-1.1%$5.00+166.0%+51.6%$106.92M$34.09M-1.92150Positive NewsADAGAdagene2.8115 of 5 stars$2.11-5.8%$7.00+231.8%-8.2%$105.57M$100K0.00260Positive NewsANROAlto Neuroscience2.2022 of 5 stars$3.76-3.5%$8.50+126.4%-67.5%$105.33MN/A-1.57N/AHLVXHilleVax1.4197 of 5 stars$2.10+0.5%$2.00-4.8%N/A$104.79MN/A-1.4720 Related Companies and Tools Related Companies BMEA Competitors PYXS Competitors EQ Competitors FATE Competitors ATOS Competitors ZNTL Competitors SPRO Competitors ADAG Competitors ANRO Competitors HLVX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KZR) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kezar Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KZR Stock Alerts